Health Check: On Garfield the Cat Day, the biotech sector purrs with deals and breakthroughs
Singular Health inks US physician network deal
Clarity clearly is undervalued, say brokers
Among other auspicious events, the 19th of June marks the end of slavery in the US, Garfield the Cat Day and the birthdays of former British PM Boris Johnson and royal temptress Wallis Simpson.
So why not add a slew of meaningful life sciences announcements, including an HIV vaccine breakthrough, to the June 19 pantheon?
Let's start with Orthocell (ASX:OCC), which reports 'compelling data' showing its Remplir nerve repair agent is superior to suture-only standard techniques.
Stitching accounts for circa 90% of the 700,000 nerve repair procedures done in the US annually.
A cuff that envelops the damaged peripheral nerves, Remplir reduces the use of stitching, which can compromise nerve repair.
Orthocell's study used a rat sciatic nerve injury model, covering 48 rodents across four treatment groups.
These cohorts covered repairs using one, three or six sutures, compared with one suture augmented with Remplir.
The rats' nerve function and regeneration were evaluated up to 12 weeks post-treatment.
The FDA ticked off Remplir in early April and the device is also approved in Canada, Hong Kong, Singapore, New Zealand and here.
Thus, the study was pitched not so much as approval as supporting the US sales rollout.
Orthocell cites a total addressable market in its target markets of US$3.5 billion, with its already-approved geographies accounting for US$1.8 billion.
The US market is worth US$1.6 billion.
Stem-cell hope for bone marrow transplant patients
NeuroScientific Biopharmaceuticals (ASX:NSB) highlights previous clinical data showing its soon-to-be acquired stem cell platform is effective in preventing graft-versus-host disease (GvHD).
The company is buying the asset, Stemsmart from the unlisted Perth-based Isopogen.
The phase I work covered adults and children with life-threatening, steroid-resistant GvHD, a common complication of bone-marrow transplants.
The data shows the treatment is safe and well tolerated, 'with no infusion related toxicities'.
Furthermore, most adults and children had a 'complete or partial resolution of symptoms and improved survival'.
Of the 10 children treated on compassionate grounds, all had survived 12 months post implant. Three of them were still alive six years post treatment.
Turning to pancreatic cancer, Amplia (ASX:ATX) reports another patient with a 'complete response' in its 55-patient trial dubbed Accent.
As close as dammit to a cure, a confirmed complete response formally is defined as all tumour lesions disappearing, with the effect maintained for at least two months.
'This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body,' the company says.
A Singularly fine US deal
Imaging medtech outfit Singular Health Group Ltd (ASX:SHG) has signed a $2 million agreement with a US physician network to develop and use Singular's 3Dicom medical imaging tool.
The compact is with Provider Network Solutions (PNS), covering physician networks in Puerto Rico, Florida, and Texas.
It covers the initial deployment of 1000 3Dicom licences, at US$800 each.
Singular pockets a further US$500,000 on 'satisfaction of AI model marketplace and image repository development and integration'.
The company hope to expand to the remaining 30 states that PNS covers.
3Dicom converts magnetic resonance imaging and computed tomography scans to enable 'immersive visualisation' with three-dimensional images.
Singular also said it had received $8 million of firm commitments in its recently-announced placement.
Meanwhile, microbiome testing house Microba Life Sciences (ASX:MAP) is on trading halt pending a capital raising.
EZZ girds for US launch
Hitherto China and locally focused, health supplements outfit EZZ Life Science (ASX:EZZ) has launched four initial products into the US after winning FDA approval.
To be sold under the new Ezzday banner, the products are made in the US and are tailor-made for American consumers.
Seeing you asked, the remedies cover de-bloating/de-gassing, vaginal probiotics, skincare and colon detox. Readers can draw their own conclusions as to what that means about the State of the Nation in Trumpian times.
Initially, the products will be sold via Amazon and Shopify.
Locally EZZ sells via more than 600 chemists and globally via 750 ecommerce platforms, including China's Douyin and Tmall.
The company values the US supplements market at US$100 billion a year, pipping China's US$80 billion opportunity.
US health secretary Robert F Kennedy Junior (RFK Jr) has a special interest in health supplements, which at the very least shouldn't harm EZZ's US ambitions.
EZZ shares have been on a tear – up 33% over the last month – but they are still well shy of the record $5 peak in October last year.
HIV jab spells hope for end to '45-year pandemic'
Speaking of RFK Jr, the FDA has approved a drug that is meant to protect against HIV with a single administration every six months.
Yep – it's a vaccine – so maybe the health czar isn't as avowedly anti-vaxx as we all think.
Marketed as Yeztugo by Gilead Sciences, lenacapavir is seen as the best hope of knocking HIV – in effect a 45-year pandemic – on its head.
Clinicians say the drug is much more powerful than the current oral treatments and almost 100% effective.
'This is a historic day in the decades-long fight against HIV,' Gilead CEO Daniel O'Day said.
'Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic.'
The drug has a list price of US$28,218 ($43,300). But Gilead may provide the vaccine free to non-insured patients.
Have investors underestimated Clarity?
Is radiopharmacy outfit Clarity Pharmaceuticals (ASX:CU6) a case of 'objects in this rear view mirror are closer than you think'?
Following a series of clinical updates from Clarity, broker Canaccord values the company at $6.74 a share, a lofty 210% increment on the current price.
In March, Wilsons ascribed an even ballsier $8.25 a share.
All things being equal – and they never are – that would value Clarity at $2.6 billion.
Sector champ Telix Pharmaceuticals (ASX:TLX) is worth around $8 billion, bearing in mind it has two FDA-approved prostate cancer imaging tools and a kidney cancer consent in the offing.
Yesterday, Clarity said it has struck an agreement with US mob Spectronrx.
Spectronrx will provide 400,000 patient-ready does of its copper isotope based 64Cu-SAR-bisPSMA (for diagnosing and potentially treating prostate cancer).
In the nuclear medicine game, gaining access to nearby doses is half the battle. But this agent's generous half-life means it can be distributed across all 50 US states.
Clarity recently announced promising phase II results for 64Cu-Sartate (neuroblastoma) and 64Cu-SAR-Bombesin (PSMA-negative prostate cancer).
Another program, Secure, focuses on identifying and treating metastatic castration-resistant prostate cancer.
Clarity currently has no approved products, but Canaccord expects 64Cu-SAR-bisPSMA to be on market by mid 2027.
'Recent commercial agreements should remind the market that this potential best-in-class asset could be closer than we think.'
The firm reckons Clarity can win a 20% share of the US market, for US$520m in peak sales.
Your columnist's nuclear science credentials – the ones plucked from a Weeties pack – are out of date.
But it looks like Telix should have one eye on the rear-view mirror and the other on the road ahead.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
2 hours ago
- ABC News
Astronomers get first look deep inside a star during supernova explosion
Astronomers have peered directly at a star's inner layers for the first time, thanks to a stellar explosion 2.2 billion light-years away. The star was stripped of its outer shells, revealing its dense innards to the Keck Observatory in Hawaii just after it exploded in a cataclysmic blast. The star's demise, reported in the journal Nature, also confirms current theories about stellar evolution. Study lead author and Northwestern University astronomer Steve Schulze said their team was "awestruck" by the discovery, but there's plenty still to uncover about the supernova dubbed 2021yfj. Stars burn for billions of years, but their deaths can be very abrupt, with supernova explosions over in a matter of hours. Despite detecting thousands of supernovas, their brevity makes it difficult for astronomers to study them in detail. Generally, stars burn by converting hydrogen into progressively heavier elements via nuclear fusion. When massive stars run out of hydrogen, they collapse in on themselves, producing a violent supernova explosion. But before the explosion, astronomers believe a star's heavier elements settle into onion-like layers, with the heaviest — iron — at the core of the biggest stars. That iron core is surrounded by layers of lighter elements such as argon, sulphur and silicon, which are in turn surrounded by elements that are lighter still, such as oxygen and carbon. Helium and hydrogen form the outermost layers, or the skin of the onion. Until now, Dr Schulze said, it was nearly impossible to see any of these deeper layers directly. "The silicon- and sulphur-rich layer is buried under many other materials and is therefore inaccessible [by telescopes] under normal circumstances." The astronomers were able to see the true weirdness of 2021yfj because they took advantage of a lucky cosmic moment. In September 2021, a survey of the night sky by the Zwicky Transient Facility in California spotted a bright flash in a star-forming region some 2.2 billion light-years from Earth. Dr Schulze and their team raced to see if any observatories could collect a spectrum — a record of light from the explosion showing elements present — shortly after the supernova happened. The Keck Observatory managed to provide one within a day of the explosion. But rather than seeing the relatively light element shells usually present in a supernova, such as carbon, nitrogen and oxygen, the spectrum was full of heavier elements: silicon, sulphur, and argon. This means that something pulled those upper layers off the star before it exploded, exposing the layers closer to the core. Brad Tucker, an astronomer at the Australian National University who wasn't involved in the research, said this find was an "important confirmation" of stellar structure. "We've always modelled it this way. We've had evidence from our understanding of nuclear physics. The researchers don't know exactly what removed so many outer layers of the star before the supernova. The most likely theory, they suggest, is a massive star more than 100 times the mass of our Sun fired its outer material off in waves right before exploding. Dr Schulze said this behaviour had been seen with a few other stars — although only with their lighter upper hydrogen and helium layers, not the heavier elements below. Dr Tucker agreed this was a likely explanation, and that a star ejecting its lower layers prior to explosion was "the next logical step" after venting the lighter elements. But there are still puzzles in the data. The researchers also found small amounts of helium in the star's debris, for instance, which they don't yet have a good explanation for. Dr Schulze said the supernova they observed was "only one among the more than 10,000 supernovas known, making it a very rare event". Nevertheless, they're confident that astronomers will be able to observe another partially denuded star exploding and learn more about the strange phenomenon. New facilities, like the Rubin Observatory in Chile, allow astronomers to see supernovas in much greater number, according to Dr Tucker. "We now have surveys that are getting hundreds to thousands of supernovas a year, whereas previously we'd get dozens to maybe 100," he said.
News.com.au
8 hours ago
- News.com.au
‘First contact': Fears as alien object speeds toward earth
A mystery object tearing towards Earth at break-neck speed has raised fears that aliens are on their way here. Scientists warn that the odd entity, which astronomers are calling 31/Atlas, could be an ET craft set to launch probes on our planet. Estimated at more than 12 miles (19 kilometres) wide, it is whizzing through our solar system on a trajectory that will bring it within about 170 million miles (274 million kilometres) of us on December 19. A trio of scientists from Harvard University, led by astrophysicist Avi Loeb, have published a paper speculating whether it could be 'hostile' extraterrestrial technology. Nick Pope, who used to investigate UFOs for the UK's Ministry of Defence, said: 'It is not beyond the realms of science fiction that 31/Atlas could be an alien spaceship of some kind. 'It's an unusual size, unusual acceleration, unusual course and unusual behaviour — those things combined very closely match a sort of mapping or survey mission. 'Of course, this could turn out to be just a comet or an asteroid — albeit an interstellar one, so interesting and incredibly rare. 'The good thing is this is a testable hypothesis. 'The clock is ticking down. We will know soon enough whether we're dealing with first contact … or just a big rock.' Here, Nick sets out the six key theories proposed by Harvard experts. 1. It's too large to be an asteroid. We do know asteroids in our solar system range in size but this is much bigger than average 2. Its rate of acceleration seems unusual for a natural object. The European Space Agency and Hubble space telescope calculate it is travelling at about 130,000mph (209,215km/h) NASA says at that speed, it is the fastest solar system visitor. 3. We spotted it very late. This was because it was coming in from the centre of the galaxy, where there are a lot of obstacles, light and stars. If you wanted to covertly send a probe into our solar system, this is exactly the course you would choose. 4. Its course makes it very hard to intercept. At critical points where it might do something technological, such as perform a non-natural manoeuvre, it is blocked by the sun. 5. Passing close to Venus, Mars and Jupiter. This is like a mapping or survey mission. There is a very low probability of that happening naturally — the report suggests close to 0.005 per cent. That is statistically minute. 6. We won't see it. At its closest approach, the sun will be between the Earth and Atlas so we won't be able to see it. Again, this is exactly the course you would choose, as it can do all its sneaky braking manoeuvres and changes of course without us seeing it. It might do one of two things if this is technological. It could change course and come to Earth itself. Or it could, if it's a mothership, deploy some probes that would come to Earth.
News.com.au
19 hours ago
- News.com.au
Sounds serious: NYC noise pollution takes a toll
Tim Mulligan moved to central Manhattan so he could be closer to work and avoid a daily ordeal on the rattling, screeching subway, just one part of the urban noisescape that tests New Yorkers every day. "Even with your earbuds in, turned all the way up, you can't hear anything for the whole commute, and you're ruining your ears at that level," said Mulligan, a US Marines veteran who lives with PTSD. At his home close to New York's tourist hub Times Square, Mulligan has sealed his windows with high-density soundproof foam, draped them with double thick curtains and invested in earplugs to sleep. On the street he has resorted to noise-cancelling headphones, and he prefers bikes to the subway for getting around. New Yorkers and visitors to the megacity of 8.5 million people are bombarded with blaring sirens, loud locals, raucous bars and car horns almost constantly. A city-wide hotline received 750,000 noise complaints in 2024, the most commonly complained about quality of life issue. The city that never sleeps, perhaps because it can't, is one of the few built up US areas with a noise code regulating sound from vehicles, construction, businesses, and recreation. It has even installed cameras with sensors to detect and penalize violators. Nine-in-ten New Yorkers are at risk of hearing loss from daily exposure to noise levels exceeding 70 decibels, the healthy average, a Columbia University study conducted between 2010 and 2012 found. The report's author, professor Richard Neitzel, is now leading the first national study on noise in which 200,000 volunteers wear smart watches to track sound levels. "It looks like somewhere around one-in-four Americans are exposed to noise levels that could hurt their hearing over the long term," said Neitzel, a professor at the University of Michigan. - 'You can't undo it' - Among young people aged 18 to 25, the primary source of excess noise exposure comes from headphones. Overall, more people are exposed to high levels of environmental noise than to noise from their headphones, Neitzel added. Although the percentage of the population exposed to noise is similar to those exposed to air pollution, acoustic issues are not prioritized by residents and officials like air quality is, Neitzel said. There is clear evidence that excess noise is linked to poor sleep, cardiovascular issues, depression, cognitive decline, premature births and poor academic performance. Tinnitus, a permanent ringing in the ear affecting three out of 20 study participants, is increasingly prevalent. Loud music is even used to promote increased consumption, said Shane Newman, who manages a popular Mexican restaurant in Manhattan's trendy Hudson Yards development. "You have a drink in the music, it feels like a nice vibe and... they end up staying longer," he told AFP. Audiologist Michele DiStefano said the effects of noise on well-being have "not really been studied well enough." "The longer you have the exposure, and the higher the level, the (greater) degree of hearing loss you'll have" -- particularly for young people, she warned. "Once it does affect your hearing, you can't undo it, but you can actually prevent it," she said. "There's really a push to educate the younger generations on how you don't have to just have really loud noise at a concert -- it can be cumulative."
